These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8523234)

  • 1. Failure to detect dopaminergic neuroblastoma in a mass-screening system.
    Naito H; Takeda T; Hanai J
    J Pediatr Surg; 1995 Sep; 30(9):1317-8. PubMed ID: 8523234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for neuroblastoma and age-specific incidence.
    Moe PJ
    Acta Paediatr; 1999 Apr; 88(4):362-4. PubMed ID: 10342530
    [No Abstract]   [Full Text] [Related]  

  • 3. Results of mass screening for neuroblastoma in Sapporo, Japan.
    Takeda T; Nishi M; Shimada M; Nakadate H; Hatae Y; Naito H; Hanai J; Kawai T; Takasugi N
    Prog Clin Biol Res; 1991; 366():595-601. PubMed ID: 2068178
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chemotherapy of radically unresectible neuroblastoma in the 1st 18 months of life. Importance of quantitative determination of dopamine, vanilmandelic and homovanillic acids].
    Zeder B; Käser H; Wagner HP
    Helv Paediatr Acta; 1974 Jun; 29(2):95-104. PubMed ID: 4436123
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sensitivity and specificity of the determination of urinary catecholamines and their acid metabolites in the diagnosis of neuroblastoma in children].
    Horsmans Y; Desager JP; Harvengt C
    Bull Cancer; 1990; 77(10):985-9. PubMed ID: 2249018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass screening for neuroblastoma targeting children age 14 months in Sapporo City: a preliminary report.
    Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Hirama T
    Cancer; 1998 May; 82(10):1973-7. PubMed ID: 9587132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for neuroblastoma in North America--preliminary results from the Quebec project.
    Woods WG; Tuchman M; Lemieux B
    Prog Clin Biol Res; 1991; 366():585-94. PubMed ID: 2068177
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopaminergic neuroblastoma as a poor prognostic subgroup.
    Nakagawara A; Ikeda K; Tasaka H
    J Pediatr Surg; 1988 Apr; 23(4):346-9. PubMed ID: 3385588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Method of measurement of urinary homovanillic acid and vanillylmandelic acid by gas chromatography-mass spectrometry suitable for neuroblastoma screening.
    Seviour JA; McGill AC; Dale G; Craft AW
    J Chromatogr; 1988 Nov; 432():273-7. PubMed ID: 3220894
    [No Abstract]   [Full Text] [Related]  

  • 10. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
    Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
    Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass screening of neuroblastoma in Sapporo City, Japan.
    Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple coloured-paper thin-layer chromatography test as a backup procedure for vanillylmandelic acid and homovanillic acid evaluation in a neuroblastoma screening program.
    Mathieu P; Philip T; Greffe J; Montegue A; Lacroix C
    Clin Chim Acta; 1993 Nov; 220(2):229-32. PubMed ID: 8111967
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical validation of urine 3-methoxytyramine as a biomarker of neuroblastoma and comparison with other catecholamine-related biomarkers.
    Lam L; Woollard GA; Teague L; Davidson JS
    Ann Clin Biochem; 2017 Mar; 54(2):264-272. PubMed ID: 27235704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a rapid and reliable method for mass screening for neuroblastoma in infants.
    Schilling FH; Oberrauch W; Schanz F; Treuner J
    Prog Clin Biol Res; 1991; 366():579-83. PubMed ID: 2068176
    [No Abstract]   [Full Text] [Related]  

  • 15. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany.
    Berthold F; Baillot A; Hero B; Schurr P; Nerenz A; Hunneman DH; Sander J
    J Clin Oncol; 1999 Apr; 17(4):1200. PubMed ID: 10561179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can mass screening for neuroblastoma detect patients with low vanillylmandelic acid and high homovanillic acid?
    Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
    Acta Paediatr Jpn; 1989 Dec; 31(6):742-4. PubMed ID: 2516402
    [No Abstract]   [Full Text] [Related]  

  • 17. Screening infants for neuroblastoma: discovery of alkaptonuria in one case.
    Mathieu P; Prevel A; David L; Bergeron C; Bory C; Chauvin F; Dia S; Frappaz D; Greffe J; Mathieu M; Philip T
    Clin Chim Acta; 1997 Aug; 264(2):255-9. PubMed ID: 9293385
    [No Abstract]   [Full Text] [Related]  

  • 18. The relationship between homovanillic/vanillylmandelic acid ratios and prognosis in neuroblastoma.
    Nishi M; Miyake H; Takeda T; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hirama T; Ishikawa Y; Kudoh T; Azuma H; Takase A
    Oncol Rep; 1998; 5(3):631-3. PubMed ID: 9538165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics of urinary excretion of vanilmandelic and homovanillic acids in cases of neuroblastoma during therapy].
    Lamedica G; Falcone R; De Bernardi B; Canini S
    Minerva Pediatr; 1978 Jan; 30(2):137-46. PubMed ID: 642879
    [No Abstract]   [Full Text] [Related]  

  • 20. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors.
    LaBrosse EH; Com-Nougué C; Zucker JM; Comoy E; Bohuon C; Lemerle J; Schweisguth O
    Cancer Res; 1980 Jun; 40(6):1995-2001. PubMed ID: 7371035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.